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Abstract: Quantum dots (QDs) and apomorphine were incorporated into liposomes to eliminate 
uptake by the liver and enhance brain targeting. We describe the preparation, physicochemical 
characterization, in vivo bioimaging, and brain endothelial cell uptake of the theranostic 
liposomes. QDs and the drug were mainly located in the bilayer membrane and inner core of 
the liposomes, respectively. Spherical vesicles with a mean diameter of ∼140 nm were formed. 
QDs were completely encapsulated by the vesicles. Nearly 80% encapsulation percentage was 
achieved for apomorphine. A greater fluorescence intensity was observed in mouse brains 
treated with liposomes compared to free QDs. This result was further confirmed by ex vivo 
imaging of the organs. QD uptake by the heart and liver was reduced by liposomal incorporation. 
Apomorphine accumulation in the brain increased by 2.4-fold after this incorporation. According 
to a hyperspectral imaging analysis, multifunctional liposomes but not the aqueous solution 
carried QDs into the brain. Liposomes were observed to have been efficiently endocytosed 
into bEND3 cells. The mechanisms involved in the cellular uptake were clathrin- and caveola-
mediated endocytosis, which were energy-dependent. To the best of our knowledge, our group 
is the first to develop liposomes with a QD-drug hybrid for the aim of imaging and treating 
brain disorders.
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Introduction
Brain targeting is one of the most challenging areas for researchers, as ,1% of drugs 
reach the brain, regardless of the physicochemical properties of the drug.1 The blood–
brain barrier (BBB) is formed by the capillary endothelium and restricts the perme-
ability of exogenous molecules, especially hydrophilic ones.2 Difficulties with drug 
brain delivery led to the development of nanoparticles, such as lipid nanoparticles, 
polymeric nanoparticles, and liposomes, which carry drugs into the brain by masking 
the BBB’s limiting characteristics. Among these, liposomes have gained much atten-
tion because of their nontoxicity and structural similarity to that of cells. Liposomes 
can fuse with cells, facilitating the transport of drugs across biomembranes.3
Liposomes can be developed for further use to track whether drugs are specifically 
delivered to target organs. Fluorescent dyes are often incorporated with liposomes 
to monitor liposomal distributions. However, they are photo unstable and have low 
brightness. A new class of semi-conductor-based quantum dots (QDs) has recently 
emerged as an imaging reagent which can overcome the drawbacks of conventional 
organic fluorophores.4 QDs have narrow band emissions together with large ultraviolet 
absorption spectra, which enable multiplex imaging under a single light source.5
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Although some drugs can be grafted onto the surface 
of QDs via covalent and ionic bonding, the quantities of 
drug molecules which can be attached to QD surfaces are 
limited. Drug-conjugated QDs also take a longer time to be 
endocytosed.5 It was proposed that liposomes can be used as 
a carrier for loading considerable amounts of both QDs and 
drugs. To meet increasing needs for brain disorder treatments, 
new nanocarriers need to be developed in order to improve 
the diagnostic accuracy and therapeutic efficacy.6 In this 
work, we developed a new theranostic nanocarrier composed 
of liposomes, QDs, and an anti-Parkinson’s drug for targeted 
and sustained imaging and drug delivery. Apomorphine was 
used as the model drug in the present study. It is approved 
as rescue medication for Parkinson’s disease, particularly to 
treat “off” periods by injection.7 However, its inherent insta-
bility and short half-life (about 41 minutes) have confined 
its clinical applicability.8 Its inclusion in nanoparticles may 
be beneficial to overcome these shortcomings.
Multifunctional liposomes integrating QDs and 
  apomorphine have become effective materials for synchro-
nous diagnosis and treatment. Vesicle size and distribution 
can be detected by laser light scattering. The morphology of 
liposomes was examined by transmission electron micros-
copy (TEM). The in vivo targeted efficiency of liposomes to 
the brain was verified by real-time imaging and apomorphine 
brain accumulation. We also used hyperspectral imag-
ing to gain information about the existence of theranostic 
liposomes and QDs in the brain. An immortalized mouse 
brain   endothelial cell line, bEND3, was used as an in vitro 
BBB model to elucidate mechanisms of endocytosis by 
nanocarriers.
Materials and methods
Materials
Apomorphine HCl, cholesterol, stearylamine, chlorpromaz-
ine, filipin, amiloride, and sodium azide were purchased from 
Sigma-Aldrich (St Louis, MO). Egg phosphatidylcholine 
(99%) and distearoylphosphatidylethanolamine-polyethylene 
glycol with a mean molecular weight of 5000 were obtained 
from Nippon Oil (Tokyo, Japan). Qdot 800 ITK® carboxyl 
QDs were supplied by Invitrogen (Carlsbad, CA).
Preparation of multifunctional liposomes
The multifunctional liposomes were prepared by a thin-
film hydration method. Briefly, phosphatidylcholine (2%, 
w/v), cholesterol (0.8%), stearylamine (0.4%), and distea-
roylphosphatidylethanolamine-polyethylene glycol (0.8%) 
were dissolved in a chloroform:methanol (2:1) mixture. 
The organic solvent was evaporated in a rotary evaporator 
at 50°C. Solvent traces were removed under vacuum for 
6 hours. The lipid film was hydrated with double-distilled 
water by high-shear homogenization (Pro 250; Pro Scientific, 
Monroe, CT) for 10 minutes. Meanwhile, apomorphine 
(0.04%) and QDs (0.2%) were added to the mixture. The 
dispersion was subjected to probe sonication (VCX 600; 
Sonics and Materials, Newtown, CT) by a continuous mode 
for 30 minutes. The sonication energy was set at 35 W.
Vesicle size and zeta potential
The average diameter and zeta potential of the theranostic 
liposomes were measured by a laser-scattering method (Nano 
ZS 90; Malvern, Worcestershire, UK). The nanosystems were 
diluted 100-fold with double-distilled water before detection. 
The measurement was repeated three times per formulation 
for three samples.
TEM examination
The liposomal morphology was examined by an electron 
microscope (H-7500; Hitachi, Tokyo, Japan). One drop of the 
liposomal dispersion was positioned on a carbon-film-coated 
copper grid to form a thin-film specimen, which was stained 
with 1% phosphotungstic acid. Then, samples were examined 
and photographed.
Encapsulation efficiency of QDs  
and apomorphine in liposomes
Encapsulation percentages of QDs and apomorphine in 
liposomes were evaluated by atomic absorption spectro-
photometry (Z-5000; Hitachi) and high-performance liquid 
chromatography (L-2000 series; Hitachi), respectively. 
The dispersion was centrifuged at 48,000 g and 4°C for 
30   minutes in a Beckman Optima MAX® ultracentrifuge 
(Beckman Coulter, Fullerton, CA), after which the super-
natant was withdrawn. We confirmed a complete solubiliza-
tion of apomorphine HCl in liposomal systems because of 
its high aqueous solubility. Thus, no drug crystal particles 
could be observed in the precipitates. Subsequently, the 
supernatant was filtered with a 0.45 µm poly(vinylidene 
fluoride) syringe. The resulting solution was analyzed for 
the amount of selenium from the QDs and apomorphine. 
The high-performance liquid chromatography method for 
apomorphine was described in our previous report.8 The 
encapsulation efficiency was obtained with the following 
equation: (total amount of QDs or apomorphine – amount 
of QDs or apomorphine in the supernatant)/(total amount of 
QDs or apomorphine).
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1600
Wen et alInternational Journal of Nanomedicine 2012:7
In vivo and ex vivo bioimaging analyses
Female nude mice (National Laboratory Animal Center, 
Taipei, Taiwan) at 10 weeks old were anesthetized with 
isoflurane. Free QDs (control group) or liposomes with QDs 
(liposomes + QDs + drug) were injected intravenously through 
the tail vein with a volume of 6 µL/g. The concentrations of 
apomorphine and QDs in the vehicles were 0.04% (w/v) and 
0.2%, respectively. In vivo mouse imaging was acquired with 
an IVIS® spectrum imaging system (Xenogen, Alameda, 
CA) linked to a computer running Living Image® software 
(v 3.1; Caliper LifeSciences, Hopkinton, MA).   Animals were 
positioned on a heating pad maintained at 37°C. Images were 
acquired at various time points post-injection. Optical excitation 
was performed at 465 nm, and the emission wavelength was 
detected at 820 nm. The fluorescence signal was exhibited 
after deduction of the background of the nude mouse itself. 
All experiments were repeated on at least three animals, and 
representative pictures are shown (Figures 2–4).
Animals were sacrificed 60 minutes after administra-
tion by decapitation. The brain, heart, lungs, liver, kidneys, 
and spleen were harvested and washed with normal saline. 
These organs were placed in a chamber of the IVIS system 
for ex vivo fluorescence imaging analysis. All experiments 
were approved by the Institutional Animal Care and Use 
Committee of Chang Gung University in accordance with 
National Institute of Health guidelines.
Hyperspectral imaging
The  blank,  control  (QDs  only),  and  experimental 
(  liposomes + QDs + drug) mice were decapitated 60 minutes 
after injection. The whole brains were dissected and cryosec-
tioned at 20 µm in thickness. The hyperspectral imaging with 
structural photograph was performed under the CytoViva 
Hyperspectral Imaging System (Cytoviva, Auburn, AL). At 
first, the unique spectral signatures of liposomes, QDs, and 
liposomes with QDs were collected. Then the brain sections 
were hyperspectrally imaged and structurally photographed. 
Finally, to confirm the presence and location of liposomes, 
QDs, and liposomes with QDs within the brain sections, the 
spectral data of each pixel in the brain sections were analyzed, 
compared, and matched to the unique spectral signatures of 
liposomes, QDs, and liposomes with QDs.
Apomorphine accumulation in the brain
After sacrificing the mice at 60 minutes post-injection, 
their brains were removed and their weights were recorded. 
Brain tissue was placed in a test tube and homogenized 
with 0.1 N HCl (1 mL) at 700 revolutions per minute 
for 10 minutes. The resulting mixture was centrifuged at 
3000 g for 10 minutes. The supernatant was filtered with a 
poly(vinylidene fluoride) syringe, and then the apomorphine 
amount in the brain was determined by high-performance 
liquid chromatography.
bEND3 cell uptake
bEND3  cells  (American Type  Culture  Collection, 
Manassas, VA) were grown according to the supplier’s 
instructions. Cells were maintained in a humidified cell 
culture incubator at 37°C and 10% CO2 in room air. Cells 
were trypsinized and seeded at 105 cells/well. The cellular 
uptake experiment was initiated by adding multifunctional 
liposomes (liposomes + QDs) or QDs in phosphate-buffered 
saline (200 µL) for 2 hours at 37°C. The experiment was 
terminated by washing the cells three times with phosphate-
buffered saline. 4′,6′-diamidino-2-phenylindole (DAPI) at 
100 ng/mL was added to the cell medium to stain nuclei. 
Cells were examined under a fluorescence microscope (IX81; 
Olympus, Tokyo, Japan). For each condition, three inserts 
were assayed.
Endocytosis inhibitor treatment
bEND3 cells were pretreated with 50 µg/mL chlorpromazine, 
10 µg/mL filipin, 250 µg/mL amiloride, or 1000 µg/mL 
sodium azide for 15 minutes at 37°C in a humidified atmo-
sphere with 10% CO2. Subsequently, cells were washed with 
phosphate-buffered saline. Liposomes or the QD solution 
was added. The endocytosis experiment was performed as 
described in the previous section.
Statistical analysis
Statistical analysis was done using unpaired t-test or analysis 
of variance (ANOVA). P , 0.05 was accepted as statistically 
significant. Values are expressed as the mean ± standard 
deviation. Error bars are used to represent the standard 
deviation.
Results
Physicochemical characterization  
of the liposomes
The average diameter, polydispersity index, and zeta potential 
of the liposomal formulations are summarized in Table 1. 
From the dynamic light scattering determination, the size 
of all liposomes were around 140 nm and had a polydis-
persity index ,0.25, demonstrating that the vesicles had a 
narrow size   distribution. The size of liposomes with QDs 
  (liposomes + QDs) was estimated to be 133 nm, which was 
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smaller than blank liposomes (145 nm). No significant differ-
ence (P . 0.05) in vesicle size was found between formulations 
with the drug (liposomes + drug and liposomes + QDs + drug) 
and plain liposomes. The zeta potential showed that blank lipo-
somes were positively charged to 59 mV . The surface potential 
did not change (P . 0.05) in the presence of apomorphine 
(  liposomes + drug). The addition of QDs slightly but signifi-
cantly (P , 0.05) reduced the zeta potential to 50 mV .
Figure 1A reveals the structure of blank liposomes by 
TEM. It appears that the vesicles had a uniform spherical 
shape with a smooth surface. Figure 1B demonstrates that 
some QDs were found in the liposomal surface. This incorpo-
ration seemingly did not affect the integrity of the liposomal 
bilayers or structure. TEM micrographs of blank liposomes 
and QD-loaded liposomes revealed average diameters 
of ∼150 and ∼130 nm, respectively, which were consistent 
with data obtained by light scattering. A proposed scheme of 
the liposomal structure is given in Figure 1C. Since apomor-
phine is a hydrophilic molecule, it should be encapsulated 
within the aqueous interior. QDs and apomorphine could be 
located in separate regions of the structure.
Table 2 shows the extents of QD and apomorphine 
encapsulation in liposomes. QDs had a nearly complete 
encapsulation efficiency of 97%. Drug loading prior to the 
addition of QDs slightly increased QD encapsulation to 
99%. A satisfactory drug-loading percentage of .75% was 
achieved regardless of whether QDs were present or not.
In vivo and ex vivo bioimaging analyses
The objective of the in vivo imaging was to observe the time 
course of fluorescent signals emitted from the QDs in mice. 
Figure 2 shows the fluorescence intensity distribution as a 
function of time for the QD solution (left side) and QD-loaded 
liposomes (liposomes + QDs + drug, right side). The fluores-
cence derived from QDs was visualized immediately following 
the injection. A more significant distribution was observed for 
liposomes compared to the control. Brain uptake increased after 
the QDs were incorporated into liposomes. Moreover, free QDs 
were rapidly eliminated from the brain. The fluorescence in the 
brain lasted up to 60 minutes for the liposomal group. With 
Table 1 The characterization of the multifunctional liposomes by 
vesicle size and zeta potential
Formulation Size (nm) Polydispersity  
index
Zeta potential   
(mV)
Liposomes 145.2 ± 2.5 0.23 ± 0.02 58.6 ± 1.4
Liposomes + QDs 132.8 ± 0.7 0.16 ± 0.01 50.4 ± 0.4
Liposomes + drug 142.4 ± 0.5 0.22 ± 0.01 57.6 ± 2.4
Liposomes +  
QDs + drug
142.0 ± 0.3 0.20 ± 0.003 50.3 ± 0.3
Note: Each value represents the mean ± standard deviation (n = 3).
B A
Theranostic liposomes
Apomorphine HCl
Quantum dots
C
100 nm 100 nm
Figure 1 Transmission electron microscopic micrograph of (A) blank liposomes and (B) liposomes incorporated with quantum dots. The scale bar is 100 nm. The scheme 
of the expected structure of the theranostic liposomes with quantum dots and apomorphine is shown in (C).
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respect to the control group, the area near the liver seemed to 
maintain a high fluorescence signal for 35 minutes.
Harvested organs were imaged 60 minutes post-injection 
to evaluate the ex vivo organ-specific uptake. Results of the 
biodistribution are shown in Figure 3. The QDs mainly accu-
mulated in the brain, heart, lungs, liver, and spleen, but were 
sparsely distributed in the kidneys (Figure 3E). Liposomes 
exhibited a stronger signal in the brain than the free control 
(Figure 3A). The same trend was observed in the lungs and 
spleen (Figure 3C and F). The injection of free QDs showed 
a significantly greater distribution in the liver, confirming 
the in vivo real-time profiles. QDs from the aqueous solution 
were also largely distributed in the heart (Figure 3B).
Hyperspectral imaging and apomorphine 
accumulation in the brain
We used hyperspectral imaging to detect the QD fluorescence 
of brain sections. Hyperspectroscopy is an imaging system 
wherein the spatial region of samples is scanned by multiple 
different wavelengths. Each pixel for a given image possesses 
a complete spectrum associated with it. All spectra acquired 
from the samples were correlated with the classified spectra 
of the particles/vesicles tested. Free QDs, blank liposomes, 
and theranostic liposomes were scanned for wavelengths 
ranging 400–800 nm as depicted in Figure 4A. The spectra of 
various nanoparticles could be differentiated from each other. 
Figure 4B–D present the fluorescence images of brain slices 
treated by normal saline, free QDs, and multifunctional lipo-
somes, respectively. No signal was detected in the untreated 
and free QD-treated images. Some spots of strong fluores-
Table  2  The  encapsulation  efficiency  (%)  of  selenium  and 
apomorphine in the multifunctional liposomes
Formulation Selenium Apomorphine
Liposomes + QDs 96.86 ± 1.33 –
Liposomes + drug – 79.48 ± 7.01
Liposomes + QDs + drug 99.42 ± 0.19 76.66 ± 5.03
Note: Each value represents the mean ± standard deviation (n = 4).
Abbreviation: QDs, quantum dots.
2.5 min 0 min
60 min 55 min
50 min 45 min
10 min 5 min 7.5 min
25 min 20 min 17.5 min 15 min 12.5 min
35 min 30 min
0 min
40 min
p/sec/cmˆ2/sr
1.5
2.0
2.5
×107
Color scale
Min = 1.02e7
Max = 2.84e7
Figure 2 Fluorescence distributions of a representative animal at different time points following an intravenous injection of free quantum dots (0.2%) in an aqueous solution 
(left side) and theranostic liposomes with quantum dots (right side). The injection volume of the vehicles was 6 µL/g.
Note: The scale on the right panel is the color map for photon counts.
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cence were observed with liposomal treatment. The spectra 
of brain sections treated with liposomes were classified by 
matching the obtained spectra from the particles/vesicles. 
Classified spectra were pseudo-colored and mapped onto 
the image shown in Figure 4E. The yellow and white colors 
represent multifunctional and blank liposomes, respectively. 
This image shows that intact liposomes had penetrated into 
the brain. The right panel of Figure 4E indicates the percent-
ages of different particles/vesicles obtained from the scanned 
sections. No free QDs were found in any samples.
Next, we examined the apomorphine concentration in 
the brain after intravenous administration of the aqueous 
solution and liposomes (liposomes + QDs + drug) for 1 hour. 
Figure 5 shows a significantly higher uptake (P , 0.05) of 
the drug with liposomes compared to that in the solution. 
The drug brain uptake of liposomes increased 2.4-fold that 
of the free control. This indicates the rapid elimination of 
free apomorphine in the circulation.
bEND3 cell uptake
The internalization of QDs or liposomes in bEND3 cells 
was visualized by fluorescence microscopy. Many studies 
used primary cultures of brain microvessel endothelial 
cells to constitute an in vitro BBB model. However, 
primary cultures limit the generation of material for 
molecular and biochemical assays since cells grow 
AB
CD
EF
Lungs
Kidneys Spleen
Liver
Heart Brain
Image
Min = 8.35e7
Max = 8.42e6
Color bar
Min = 3.34e6
Max = 9.00e6
9.0
8.0
7.0
×106
p/sec/cmˆ2/sr
6.0
5.0
4.0
Image
Min = 0.00
Max = 9.24e7
Color bar
Min = 8.81e6
Max = 8.81e7
0.8
0.6
×108
p/sec/cmˆ2/sr
0.4
0.2
Image
Min = 0.00
Max = 5.02e6
Color bar
Min = 2.76e6
Max = 4.84e6
4.5
4.0
3.5
×106
p/sec/cmˆ2/sr
3.0
Figure 3 Ex vivo fluorescence imaging of (A) the brain, (B) heart, (C) lungs, (D) liver, (E) kidneys, and (F) spleen excised from representative nude mice following an intravenous 
injection of normal saline (left side), free quantum dots in an aqueous solution (center), and theranostic liposomes with quantum dots (right side) for 60 minutes.
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slowly, are prone to contamination by other cells, and 
lose the BBB characteristics.9 The immortalized mouse 
brain endothelial cell line, bEND3, has become popular 
as an in vitro BBB system because of its advantages over 
primary cell culture, including the ability to maintain 
BBB characteristics through many passages, and its easy 
growth and low cost.10 bEND3 cells were incubated with 
DMSO, the QD solution, and QD-containing liposomes 
(liposomes + QDs) for 2 hours (Figure 6A–C). No drug 
was loaded in the liposomes in this experiment to avoid 
the effect of apomorphine on the cells. Cell nuclei were 
observed with blue staining by DAPI. The DMSO and 
free-QD treatments revealed no fluorescence other than 
blue staining, indicating negligible cell uptake of QDs. 
QDs internalization into the cells could be observed 
after liposomal incubation. The observed red dots shown 
in Figure 6C should be aggregates of QDs located in 
intracellular areas. The very strong red signals had shielded 
the blue staining of the nuclei.
Figure 7 is another view of cellular uptake. The left sides 
of Figure 7 show the morphology of bEND3 cells under 
visible light. The right panels of Figure 7 are the images 
under fluorescence microscopy without DAPI staining.   
A similar result was detected as compared to the images with 
A B
C D
E
Class
Unclassified
Blank liposomes
Free QDs
Theranostic liposomes
Percentage (%)
99.58
0.13
0
0.29
Endmember collection spectra
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1500
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0
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V
a
l
u
e
700
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10 µm
10.00 um
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Figure 4 The single-pixel spectra of (A) blank liposomes (white), free quantum dots (QDs) (red), and theranostic liposomes with QDs (yellow). Fluorescence distribution of 
a brain section after an intravenous injection of (B) normal saline, (C) free QDs in an aqueous solution, and (D) theranostic liposomes with QDs for 60 minutes. (E) Image 
of a brain section treated by theranostic liposomes color-coded according to the spectra of different particles/vesicles at each pixel in the field of view. Pixels that did not 
have an identifiable spectrum in a corresponding spectrum were not assigned a color. 
Note: The right panel indicates percentages of different particles/vesicles obtained from the scanned sections after a spectrum correlation check.
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DAPI staining. The bEND3 cells demonstrate negligible 
fluorescence from the blank control and free QDs solution 
as depicted in Figure 7A and B. Fluorescence microscopy 
shows that the QDs-loaded liposomes enter bEND3 cells by 
a greater quantity (Figure 7C).
Four inhibitors were used to pretreat bEND3 cells to 
elucidate the mechanisms involved in cellular uptake. 
  Chlorpromazine, filipin, amiloride, and sodium azide can 
inhibit the pathways of clathrin-mediated endocytosis, caveo-
lar endocytosis, macropinocytosis, and energy dependence, 
respectively. As compared to the liposomes-treated group 
without inhibitors (Figure 6C), chlorpromazine, filipin, 
and sodium azide treatments restrained the cellular uptake 
of QDs from liposomes as shown in Figure 8A, B, and D. 
Amiloride treatment had little influence on the internalization 
of liposomes (Figure 8C).
Discussion
Diseases related to the brain represent 35% of the burden of 
total human diseases.11 It is difficult to treat brain pathologies 
because of restrictions of the BBB against drug permeation. 
Liposomes represent a strategy for improving the brain trans-
port of chemical agents. Another emerging tool in targeted 
delivery is the multimodal carrier, in which an imaging 
agent and drug are assembled for simultaneous diagnosis 
and therapy.12 We developed a targeted delivery system 
integrating liposomes, QDs, and a drug in the present work. 
Many types of drug delivery systems have been labeled with 
QDs via synthesis methods.13 The systems developed in this 
study can be used to deliver QDs and apomorphine without 
the need for conjugation chemistry. Most liposome-QD 
hybrids were designed for cancer diagnosis.14 The present 
work shows liposome-QD delivery to the brain for theranostic 
aims for the first time.
According to the TEM results, nano-sized liposomes were 
prepared by incorporation of QDs as a part of the bilayers. 
Both TEM and light-scattering measurements indicated that 
the vesicles had a narrow distribution range, which is essential 
for regulatory purposes. The loading of QDs resulted in some 
reduction in liposomal size. This demonstrates that the QDs 
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Figure 5 Apomorphine accumulation (ng/mg) in the brain after an intravenous injection of apomorphine in an aqueous solution and theranostic liposomes.
Note: Each value represents the mean and standard deviation (n = 4).
AB C
Figure 6 Fluorescence microscopic images of endocytosis of bEND3 cells after 2 hours of incubation of (A) the blank control, (B) free quantum dots in an aqueous solution, 
and (C) theranostic liposomes with quantum dots. Cell nuclei are observed with blue staining by 4′,6′-diamidino-2-phenylindole.
Note: The red signals represent the quantum dots accumulation.
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may possess an emulsifier effect on the bilayers which caused 
this reduction. The QDs were resided on the liposomal surface 
based on the TEM images. The lipophilic molecules/materials 
always reveal high loading within phospholipid bilayers because 
of the high affinity to this lipophilic environment and unfavor-
able accommodation in aqueous core of liposomes and external 
water phase. This may result in the nearly complete entrapment 
of QDs (.97%) within the vesicles. Since the apomorphine 
concentration (0.04%) in the liposomal system was low, drug 
incorporation did not alter the vesicle size. Apomorphine HCl 
is basically a hydrophilic molecule. Both aqueous cores and 
external phase were feasible for this drug to reside in. A lower 
encapsulation efficiency of apomorphine than QDs could be 
observed because some unencapsulated drug molecules might 
locate in external phase. Nevertheless, a .75% encapsulation 
  percentage was satisfied for further in vivo experiments. The 
satisfied   entrapment can be due to low apomorphine concentra-
tion for loading and rigid liposomal bilayers for minimizing 
drug leakage. The positively charged surface of liposomes was 
attributed to the presence of stearylamine, a cationic   surfactant. 
QDs mainly located in the bilayers decreased the zeta potential 
because of some ionization of QDs with the –COOH moiety. 
A physically stable nanosystem solely stabilized by electro-
static repulsion should have a zeta potential of .|30| mV .1,15 
The zeta potential of our liposomes indicated the stability of 
the prepared formulations.
A
B
C
Figure 7 Microscopic images of endocytosis of bEND3 cells after 2 hours of incubation of (A) the blank control, (B) free quantum dots in an aqueous solution, and   
(C) theranostic liposomes with quantum dots. 
Notes: The left panels are the observations under visible (white) light. The right panels are the observations under fluorescence microscopy.
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The in vivo evaluation of whether the nanosystems play a 
significant role in brain uptake via the BBB is critical. In vivo 
bioimaging was used to assess the kinetics of the fluorescence 
activity in these mice. The free solution and liposomes with 
QDs were transported from the circulation to the brain. The 
brain level of the control solution quickly dropped thereafter, 
suggesting significant metabolism or degradation. Inclusion in 
liposomes prolonged the residence time in the brain. A previous 
study16 demonstrated the difficulty of carboxyl QD passage 
through the BBB. In addition to the brain, theranostic liposomes 
revealed greater accumulation in the lungs and spleen.   Transient 
lung accumulation after an injection of positively charged 
nanoparticles was previously described,17 which was due to the 
particles interacting with lung capillaries since they are the first 
capillary bed encountered after a tail vein injection.
It is well known that injected nanoparticles are captured 
by the reticuloendothelial system, leading to accumulation 
in the liver and spleen. The liver is the main target organ for 
QDs.18 Inclusion in liposomes reduced the accumulation of 
QDs in the liver. Cholesterol and polyethylene glycol within 
liposomal bilayers exhibit longer blood circulation and slower 
uptake by the liver.16 The low clearance of liposomes from 
the liver is favorable for sustained release in the circulation or 
targeted sites. However, a greater accumulation was observed 
for liposomal uptake in the spleen. This is reasonable since the 
spleen is a major organ for liposomal clearance.19 The much 
smaller size of the spleen than the liver could result in a lower 
total clearance of liposomes compared to free QDs. Few QDs 
or liposomes were found in renal tissues. The liposomes are 
too large for kidney excretion. The kidneys play a vital role 
in removing QDs with diameters ranging 4–6 nm. As the size 
of the QDs increases, the renal clearance significantly drops.20 
The QDs used in this study had a diameter of 20 nm. This can 
explain the negligible renal accumulation of free QDs.
Hyperspectral imaging can provide information related 
to the type and percentage of particles/vesicles in the brain. 
The technique is useful for quality control assessments of 
pharmaceutical products.20,21 Hyperspectral images showed 
that the liposomes had permeated through the BBB as intact 
vesicles. The QDs were entrapped in the liposomes and did 
not show leakage after 1 hour of incubation in the brain. 
It was inferred that the active efflux and metabolism of 
liposomes were limited, at least within the first hour. The 
liposomes could carry a large amount of apomorphine into 
the brain, resulting in higher drug accumulation compared 
to the control solution. Apomorphine is thought to be easily 
degraded.22 It can stably reside in liposomes when arriv-
ing in the brain, followed by the sustained release into the 
AB
CD
Figure 8 Fluorescence microscopic images of endocytosis of bEND3 cells after 2 hours of incubation of theranostic liposomes pretreated with (A) chlorpromazine, 
(B) filipin, (C) amiloride, and (D) sodium azide.
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external phase. In vivo applications are still concerned with 
the toxicity of QDs because they are basically carcinogenic 
and can produce oxidative stress.23 There were no free QDs 
present in the brain after the liposomal injection. Inclusion 
into liposomes may confine the acute toxicity induced by 
QDs. However, it still should be cautious that some toxicity 
may be occurred when the liposomes were decomposed to 
release free QDs in the brain.
Previous work24 suggested that QDs are unable to cross the 
BBB. The liposomal structure is similar to that of cells,25 show-
ing affinity with the BBB to increase brain transport. Cationic 
surfaces are also beneficial for opening tight junctions.9 
The liposomes protected the QDs and drug against degradation 
in serum. They are not easily destroyed in harsh environments, 
demonstrating that they are an excellent carrier for long-term 
bioimaging and drug delivery. To specifically target the brain, 
some ligands such as thiamine and transferrin were conjugated 
on the nanoparticulate surfaces.26,27 However, this ligand con-
jugation can produce some disadvantages such as a quenching 
of fluorescence, induction of toxicity, and distribution to other 
recognized organs.27,28 We developed theranostic liposomes for 
brain delivery without the need for ligand association.
We used an immortalized mouse brain endothelial cell line 
(bEND3) as the in vitro BBB model because it can express 
messenger (m)RNA and proteins for a number of tight   junction 
proteins.10 These proteins are necessary for tight junction 
formation and maintenance. Most of the presently available 
QDs were internalized by various cells, but neurons are the 
exception.23 Liposomal intervention can facilitate internal-
ization of QDs into neurons. This result proved the in vivo 
brain targeting of   liposomes. A higher uptake by cells leads to 
better molecular imaging consequences. Some organic cation-
  sensitive transporters exist in the BBB, which are involved in 
transporting cationic drugs and materials.2,29 Cationic nanopar-
ticles produce interactions with negatively charged endolyso-
somal membranes and destabilize them, followed by extrusion 
into the cytoplasm.30 Another mechanism is a concentration 
effect. The concentration of QDs loaded into liposomes was 
vastly greater than that of an equal volume of free QDs. QDs 
in liposomes can easily diffuse into cells due to a concentra-
tion gradient. A previous study31 suggested that Lipofectamine 
2000 encapsulating QDs within vesicles enhanced entry into 
the   cytoplasm of tumor cells. This is the first validation of the 
efficient internalization into brain endothelial cells by a QD-
liposome hybrid. The red dots in the cellular uptake imaging 
exhibited significant aggregation of particles. The QDs capped 
with carboxyl ligands often produce intermediate agglomera-
tion due to instability in neutral/acidic buffers.32,33 It is proposed 
that QDs are released from liposomes after fusion with cell 
membranes. The   intracellular pH of rat brain endothelial cells 
is reported to be 7.0,34 which is lower than the physiological 
environment. Thus, the aggregation of QDs could occur.
The cellular uptake experiments with inhibitor treatment 
demonstrated possible pathways, including clathrin-dependent 
and caveola-mediated endocytosis with an active energy-
dependent character. Our results suggest that liposomes can 
enter cells with no need for specific ligands. The adsorptive 
but not receptor-mediated transcytosis may be the major route 
of this delivery. However, internalization of receptors and 
their ligands by clathrin-coated pits corresponds to receptor-
mediated transcytosis.35 It could occur with theranostic 
liposomes since polyethylene glycol is recognized by low-
density lipoprotein receptors on brain endothelial cells36 
Caveolae are invaginations on the cell membrane which are 
coated with caveolin. Filipin can inhibit liposomal uptake, 
suggesting the potential transport by caveolar pathways. 
A single caveola has a diameter in the range of 50–80 nm,37 
which is smaller than the liposomal size. Caveosomes are 
formed by assembling several caveolae, and show a maximum 
size of 250 nm.38 The caveola-mediated route of liposomes 
may have occurred via caveosomes. Amiloride is an inhibitor 
of macropinocytosis. The formation of actin-driven membrane 
protrusions leads to macropinocytosis. Cell membrane ruffling 
results in the formation of large compartments as the tip of the 
ruffle fuses back with the membrane.39 Our results exhibited 
that liposomes are endocytosed via processes independent of 
macropinocytosis pathways.
Conclusion
Multifunctional liposomes can be used to deliver various 
agents such as fluorescence probes and therapeutics. We 
developed theranostic liposomes with high encapsulation of 
QDs and apomorphine, which improved fluorescence imaging 
and drug targeting to the brain. The production of liposomes 
allowed the formation of spherical vesicles with diameters 
of ,150 nm. Encapsulation of the QDs within liposomes 
avoided liver uptake. Brain targeting was thus enhanced. The 
hyperspectral analysis can be applied to distinguish the pres-
ence of various types of nanoparticles/vesicles in the brain. 
The results showed that QD-loaded liposomes, but not free, 
QDs were transported across the BBB. The liposomes were 
successfully delivered into the brain by endocytosis routes. 
Clathrin- and caveola-mediated endocytosis with an energy-
dependent mode was involved in the mechanisms of liposomal 
uptake. Targeted liposomes can be used to deliver probes and 
drugs to the brain at the same time. The toxicity of QDs and 
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drug was expected to be reduced. The developed liposomes 
provide a novel perspective for the diagnosis and treatment 
of brain disorders such as Parkinson’s disease.
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